Stryker Q1 sales $5.2B (+9.7%), organic +10.0%; lifts FY organic growth view to 8.5-9.5%, adj. EPS $11.85-$12.05

STRYKER CORP

2024-Q1 EPS reported $2.05 revenue$5,243,000,000

Reported EPS $2.05 (+33.1%); adjusted EPS $2.50 (+16.8%).
MedSurg & Neurotechnology organic sales +11.6%; Orthopaedics & Spine organic +8.0%.
Reported operating margin 18.5%; adjusted operating margin 21.9% (+80 bps).
FY 2024 organic net sales growth now expected 8.5% to 9.5% (prior range not disclosed).
Adjusted EPS guidance raised to $11.85-$12.05; expects negative FX impact of $0.05-$0.10.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

STRYKER CORP updated its first quarter 2024 guidance (raised).

Period: first quarter 2024
Guidance: raised
Result: reported results

Exact text from the filing

Stryker Corporation issued a press release on April 30, 2024 announcing its first quarter 2024 operating results.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

STRYKER CORP filing history →

Source: SEC EDGAR

accession 0000310764-24-000062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.